Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Capital Employed (2021 - 2025)

Lyell Immunopharma's Return on Capital Employed history spans 5 years, with the latest figure at 0.94% for Q3 2025.

  • For Q3 2025, Return on Capital Employed fell 58.0% year-over-year to 0.94%; the TTM value through Sep 2025 reached 0.94%, down 58.0%, while the annual FY2024 figure was 0.63%, 33.0% down from the prior year.
  • Return on Capital Employed for Q3 2025 was 0.94% at Lyell Immunopharma, up from 0.96% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.19% in Q4 2021 and bottomed at 0.96% in Q2 2025.
  • The 5-year median for Return on Capital Employed is 0.3% (2023), against an average of 0.41%.
  • The largest annual shift saw Return on Capital Employed increased 1bps in 2023 before it plummeted -61bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.19% in 2021, then fell by -6bps to 0.2% in 2022, then crashed by -65bps to 0.33% in 2023, then plummeted by -114bps to 0.72% in 2024, then crashed by -31bps to 0.94% in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Return on Capital Employed are 0.94% (Q3 2025), 0.96% (Q2 2025), and 0.86% (Q1 2025).